Adaptive Bio Offers Next Gen Cancer Tests

Founded by two brothers and spun out of the Fred Hutchinson Cancer Research Center, Adaptive Biotechnologies (ADPT) is a pioneer in immune-driven medicine with two commercial products and an extensive pipeline backed by collaborations with Microsoft and Genentech. Its core immunoSEQ research assay sequences T-cell and B-cell receptors to provide unique insights into a patient's immune system and has been used by over 2,000 academic researchers and 125 biopharmaceutical companies.

Here are three other things you need to know about Adaptive Biotechnologies:

To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.
Coming Soon: Karuna Therapeutics (KRTX)